{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T02:55:33Z","timestamp":1722826533438},"reference-count":142,"publisher":"Elsevier BV","issue":"7","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.bbapap.2013.01.041","type":"journal-article","created":{"date-parts":[[2013,2,8]],"date-time":"2013-02-08T12:31:03Z","timestamp":1360326663000},"page":"1371-1380","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Overcoming resistance to rapalogs in gliomas by combinatory therapies"],"prefix":"10.1016","volume":"1834","author":[{"given":"Michal","family":"Grzmil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian A.","family":"Hemmings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 4","key":"10.1016\/j.bbapap.2013.01.041_bb0005","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/annonc\/mdp151","article-title":"Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"20","author":"Stupp","year":"2009","journal-title":"Ann. Oncol."},{"issue":"Suppl. 5","key":"10.1016\/j.bbapap.2013.01.041_bb0010","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/nos218","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005\u20132009","volume":"14","author":"Dolecek","year":"2012","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0015","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s002800050691","article-title":"Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma","volume":"40","author":"Bower","year":"1997","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0020","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1200\/JCO.2000.18.7.1481","article-title":"Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme","volume":"18","author":"Osoba","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0025","first-page":"5159","article-title":"Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial","volume":"23","author":"Lanzetta","year":"2003","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0030","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"For, T. Treatment of Cancer Brain, G. Radiotherapy, G. National Cancer Institute of Canada Clinical Trials, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0035","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1200\/JCO.2002.06.110","article-title":"Clinical relevance of MGMT in the treatment of cancer","volume":"20","author":"Gerson","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0040","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2007.11.5964","article-title":"Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity","volume":"26","author":"Hegi","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0045","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/0277-5379(83)90012-3","article-title":"Human brain tumor xenografts in nude mice as a chemotherapy model","volume":"19","author":"Houchens","year":"1983","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0050","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0092-8674(93)90144-F","article-title":"Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression","volume":"73","author":"Kunz","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0055","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/369756a0","article-title":"A mammalian protein targeted by G1-arresting rapamycin\u2013receptor complex","volume":"369","author":"Brown","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0060","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0092-8674(94)90570-3","article-title":"RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs","volume":"78","author":"Sabatini","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0065","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0070","doi-asserted-by":"crossref","first-page":"15619","DOI":"10.1074\/jbc.M800723200","article-title":"Regulation of proline-rich Akt substrate of 40kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation","volume":"283","author":"Wang","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0075","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11060-009-0004-4","article-title":"Activation of PI3K\/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival","volume":"97","author":"McBride","year":"2010","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0080","doi-asserted-by":"crossref","first-page":"11712","DOI":"10.1158\/0008-5472.CAN-07-2223","article-title":"mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor","volume":"67","author":"Masri","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0085","doi-asserted-by":"crossref","first-page":"e47741","DOI":"10.1371\/journal.pone.0047741","article-title":"Conditional astroglial Rictor overexpression induces malignant glioma in mice","volume":"7","author":"Bashir","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0090","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.molcel.2011.08.030","article-title":"mTOR drives its own activation via SCF(betaTrCP)-dependent degradation of the mTOR inhibitor DEPTOR","volume":"44","author":"Gao","year":"2011","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0095","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","author":"N. Cancer Genome Atlas Research","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0100","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1158\/0008-5472.CAN-12-0026","article-title":"Translation regulation as a therapeutic target in cancer","volume":"72","author":"Grzmil","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0105","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1242\/jcs.02724","article-title":"Protein kinase B\/Akt at a glance","volume":"118","author":"Fayard","year":"2005","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0110","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor\u2013mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0115","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.cell.2011.02.014","article-title":"Activation of mTORC2 by association with the ribosome","volume":"144","author":"Zinzalla","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0120","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/22780","article-title":"Creation of human tumour cells with defined genetic elements","volume":"400","author":"Hahn","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0125","doi-asserted-by":"crossref","first-page":"e7147","DOI":"10.1371\/journal.pone.0007147","article-title":"Dysregulation of ribosome biogenesis and translational capacity is associated with tumor progression of human breast cancer cells","volume":"4","author":"Belin","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0130","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.cub.2005.02.053","article-title":"Rheb binds and regulates the mTOR kinase","volume":"15","author":"Long","year":"2005","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0135","doi-asserted-by":"crossref","first-page":"6361","DOI":"10.1038\/sj.onc.1209882","article-title":"Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase","volume":"25","author":"Avruch","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0140","doi-asserted-by":"crossref","first-page":"18717","DOI":"10.1074\/jbc.M414499200","article-title":"The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses","volume":"280","author":"Smith","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"Spec No. 2","key":"10.1016\/j.bbapap.2013.01.041_bb0145","doi-asserted-by":"crossref","first-page":"R251","DOI":"10.1093\/hmg\/ddi260","article-title":"Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways","volume":"14","author":"Kwiatkowski","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0150","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1101\/gad.1199104","article-title":"Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome","volume":"18","author":"Corradetti","year":"2004","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0155","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/378785a0","article-title":"Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B","volume":"378","author":"Cross","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0160","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.cell.2006.06.055","article-title":"TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth","volume":"126","author":"Inoki","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0165","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.canlet.2012.05.024","article-title":"Activation of canonical WNT\/beta-catenin signaling enhances in vitro motility of glioblastoma cells by activation of ZEB1 and other activators of epithelial-to-mesenchymal transition","volume":"325","author":"Kahlert","year":"2012","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0170","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1158\/0008-5472.CAN-10-1495","article-title":"Frizzled 4 regulates stemness and invasiveness of migrating glioma cells established by serial intracranial transplantation","volume":"71","author":"Jin","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0175","doi-asserted-by":"crossref","first-page":"8472","DOI":"10.1074\/jbc.M109.069450","article-title":"The imprinted gene PEG3 inhibits Wnt signaling and regulates glioma growth","volume":"285","author":"Jiang","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0180","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ccr.2010.03.020","article-title":"PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas","volume":"17","author":"Zheng","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0185","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.molcel.2007.03.003","article-title":"PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase","volume":"25","author":"Sancak","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0190","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/ncb1547","article-title":"Insulin signalling to mTOR mediated by the Akt\/PKB substrate PRAS40","volume":"9","author":"Vander Haar","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0195","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1017\/S0317167100034272","article-title":"Ras activation in astrocytomas and neurofibromas","volume":"25","author":"Guha","year":"1998","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0200","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ccr.2009.05.009","article-title":"Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis","volume":"16","author":"McGillicuddy","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0205","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cell.2005.02.031","article-title":"Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis","volume":"121","author":"Ma","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0210","doi-asserted-by":"crossref","first-page":"13489","DOI":"10.1073\/pnas.0405659101","article-title":"Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase","volume":"101","author":"Roux","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0215","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.cub.2008.07.078","article-title":"Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation","volume":"18","author":"Carriere","year":"2008","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0220","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/ncb1753","article-title":"Regulation of TORC1 by Rag GTPases in nutrient response","volume":"10","author":"Kim","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0225","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1126\/science.1157535","article-title":"The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1","volume":"320","author":"Sancak","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0230","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.cell.2010.02.024","article-title":"Ragulator\u2013Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids","volume":"141","author":"Sancak","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0235","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1126\/science.1207056","article-title":"mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase","volume":"334","author":"Zoncu","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0240","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.cell.2009.01.042","article-title":"Regulation of translation initiation in eukaryotes: mechanisms and biological targets","volume":"136","author":"Sonenberg","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0245","first-page":"648","article-title":"Translation initiation factors induce DNA synthesis and transform NIH 3T3 cells","volume":"2","author":"Smith","year":"1990","journal-title":"New Biol."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0250","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1038\/sj.onc.1207545","article-title":"eIF-4E expression and its role in malignancies and metastases","volume":"23","author":"De Benedetti","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0255","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/01.pai.0000135615.07325.a2","article-title":"Expression of eukaryotic initiation factor 4E in astrocytic tumors","volume":"13","author":"Gu","year":"2005","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0260","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1365-2559.2012.04236.x","article-title":"Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas","volume":"61","author":"Korkolopoulou","year":"2012","journal-title":"Histopathology"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0265","doi-asserted-by":"crossref","first-page":"e242","DOI":"10.1371\/journal.pone.0000242","article-title":"Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation","volume":"2","author":"Mamane","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0270","doi-asserted-by":"crossref","first-page":"6814","DOI":"10.1158\/0008-5472.CAN-07-0752","article-title":"Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors","volume":"67","author":"Larsson","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0275","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1083\/jcb.200112015","article-title":"Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells","volume":"158","author":"Chung","year":"2002","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0280","doi-asserted-by":"crossref","first-page":"14134","DOI":"10.1073\/pnas.1005320107","article-title":"eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression","volume":"107","author":"Furic","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0285","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.bbrc.2010.06.015","article-title":"Sox2 is translationally activated by eukaryotic initiation factor 4E in human glioma-initiating cells","volume":"397","author":"Ge","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0290","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1042\/BJ20070024","article-title":"Signalling to translation: how signal transduction pathways control the protein synthetic machinery","volume":"403","author":"Proud","year":"2007","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0295","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1750-3639.2009.00268.x","article-title":"Pi3K-mTOR signaling and AMOG expression in epilepsy-associated glioneuronal tumors","volume":"20","author":"Boer","year":"2010","journal-title":"Brain Pathol."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0300","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11060-010-0424-1","article-title":"Association between AKT\/mTOR signalling pathway and malignancy grade of human gliomas","volume":"103","author":"Li","year":"2011","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0305","first-page":"5041","article-title":"Malignant transformation by overproduction of translation initiation factor eIF4G","volume":"57","author":"Fukuchi-Shimogori","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0310","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/1097-0142(20010815)92:4<822::AID-CNCR1388>3.0.CO;2-A","article-title":"Translation initiation factor eIF-4G is immunogenic, overexpressed, and amplified in patients with squamous cell lung carcinoma","volume":"92","author":"Bauer","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0315","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/ncb1900","article-title":"Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer","volume":"11","author":"Silvera","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0320","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1677\/joe.1.06080","article-title":"Insulin and IGF-I stimulate the formation of the eukaryotic initiation factor 4F complex and protein synthesis in C2C12 myotubes independent of availability of external amino acids","volume":"185","author":"Shen","year":"2005","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0325","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1128\/MCB.05589-11","article-title":"Phosphorylation of eukaryotic translation initiation factor 4G1 (eIF4G1) by protein kinase C{alpha} regulates eIF4G1 binding to Mnk1","volume":"31","author":"Dobrikov","year":"2011","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0330","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1101\/gad.1604407","article-title":"Dissecting eIF4E action in tumorigenesis","volume":"21","author":"Wendel","year":"2007","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0335","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1158\/0008-5472.CAN-10-3112","article-title":"MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-beta signaling pathway in human glioblastoma","volume":"71","author":"Grzmil","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0340","doi-asserted-by":"crossref","first-page":"6516","DOI":"10.1158\/0008-5472.CAN-07-6188","article-title":"S6K1 plays a key role in glial transformation","volume":"68","author":"Nakamura","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0345","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1093\/emboj\/20.16.4370","article-title":"Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase","volume":"20","author":"Wang","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0350","first-page":"2260","article-title":"Phosphorylation of elongation factor 2 in normal and malignant rat glial cells","volume":"53","author":"Bagaglio","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0355","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1158\/0008-5472.CAN-05-1554","article-title":"Elongation factor-2 kinase regulates autophagy in human glioblastoma cells","volume":"66","author":"Wu","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0360","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bbrc.2011.09.038","article-title":"Inhibition of eEF-2 kinase sensitizes human glioma cells to TRAIL and down-regulates Bcl-xL expression","volume":"414","author":"Zhang","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0365","first-page":"123","article-title":"Frequent loss of PDCD4 expression in human glioma: possible role in the tumorigenesis of glioma","volume":"17","author":"Gao","year":"2007","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0370","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/neuonc\/nor033","article-title":"Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo","volume":"13","author":"Gaur","year":"2011","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0375","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1126\/science.1130276","article-title":"S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth","volume":"314","author":"Dorrello","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0380","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1128\/MCB.23.1.26-37.2003","article-title":"The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation","volume":"23","author":"Yang","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0385","doi-asserted-by":"crossref","first-page":"6034","DOI":"10.1158\/0008-5472.CAN-04-2119","article-title":"Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis","volume":"65","author":"Jansen","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0390","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1158\/0008-5472.CAN-08-2334","article-title":"Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth","volume":"69","author":"Shiota","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0395","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1038\/onc.2010.115","article-title":"PKB\/AKT phosphorylation of the transcription factor Twist-1 at Ser42 inhibits p53 activity in response to DNA damage","volume":"29","author":"Vichalkovski","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0400","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/2159-8290.CD-11-0270","article-title":"Akt\/PKB-mediated phosphorylation of Twist1 promotes tumor metastasis via mediating cross-talk between PI3K\/Akt and TGF-beta signaling axes","volume":"2","author":"Xue","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0405","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/1476-4598-9-194","article-title":"TWIST1 promotes invasion through mesenchymal change in human glioblastoma","volume":"9","author":"Mikheeva","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0410","doi-asserted-by":"crossref","first-page":"6384","DOI":"10.1038\/sj.onc.1209883","article-title":"Ribosome biogenesis and cell growth: mTOR coordinates transcription by all three classes of nuclear RNA polymerases","volume":"25","author":"Mayer","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0415","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1042\/BST0390487","article-title":"MAF1: a new target of mTORC1","volume":"39","author":"Michels","year":"2011","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0420","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1073\/pnas.88.8.3319","article-title":"Oligopyrimidine tract at the 5\u2032 end of mammalian ribosomal protein mRNAs is required for their translational control","volume":"88","author":"Levy","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0425","doi-asserted-by":"crossref","first-page":"6594","DOI":"10.1046\/j.1432-1327.2000.01753.x","article-title":"Transcription inhibitors stimulate translation of 5\u2032 TOP mRNAs through activation of S6 kinase and the mTOR\/FRAP signalling pathway","volume":"267","author":"Loreni","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0430","doi-asserted-by":"crossref","first-page":"R1046","DOI":"10.1016\/j.cub.2009.09.058","article-title":"An emerging role of mTOR in lipid biosynthesis","volume":"19","author":"Laplante","year":"2009","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0435","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.cmet.2008.07.007","article-title":"SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth","volume":"8","author":"Porstmann","year":"2008","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0440","doi-asserted-by":"crossref","first-page":"15201","DOI":"10.1073\/pnas.1103746108","article-title":"The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile","volume":"108","author":"Wang","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0445","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.molcel.2010.06.022","article-title":"Activation of a metabolic gene regulatory network downstream of mTOR complex 1","volume":"39","author":"Duvel","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0450","doi-asserted-by":"crossref","first-page":"ra82","DOI":"10.1126\/scisignal.2000446","article-title":"EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy","volume":"2","author":"Guo","year":"2009","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0455","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11060-005-9103-z","article-title":"Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas","volume":"78","author":"Jensen","year":"2006","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0460","first-page":"1962","article-title":"Overexpression of vascular endothelial growth factor isoforms drives oxygenation and growth but not progression to glioblastoma multiforme in a human model of gliomagenesis","volume":"63","author":"Sonoda","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0465","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.2174\/138955709788922610","article-title":"HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms","volume":"9","author":"Marin-Hernandez","year":"2009","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0470","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1126\/scisignal.284pe51","article-title":"mTORC1 phosphorylates the ULK1-mAtg13-FIP200 autophagy regulatory complex","volume":"2","author":"Chan","year":"2009","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0475","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/emboj.2012.32","article-title":"A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB","volume":"31","author":"Settembre","year":"2012","journal-title":"EMBO J."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0480","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.canlet.2012.09.007","article-title":"GDC-0941 enhances the lysosomal compartment via TFEB and primes glioblastoma cells to lysosomal membrane permeabilization and cell death","volume":"329","author":"Enzenmuller","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0485","article-title":"Endoplasmic reticulum stress triggers autophagy in malignant glioma cells undergoing cyclosporine A-induced cell death","author":"Ciechomska","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0490","doi-asserted-by":"crossref","first-page":"e19629","DOI":"10.1371\/journal.pone.0019629","article-title":"Downregulation of FIP200 induces apoptosis of glioblastoma cells and microvascular endothelial cells by enhancing Pyk2 activity","volume":"6","author":"Wang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0495","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cell.2006.08.033","article-title":"SIN1\/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity","volume":"127","author":"Jacinto","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0500","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.devcel.2006.10.007","article-title":"Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1","volume":"11","author":"Guertin","year":"2006","journal-title":"Dev. Cell"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0505","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1634\/theoncologist.7-1-17","article-title":"Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas?","volume":"7","author":"da Rocha","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0510","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1128\/MCB.21.3.952-965.2001","article-title":"Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a)","volume":"21","author":"Brunet","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0515","doi-asserted-by":"crossref","first-page":"16649","DOI":"10.1074\/jbc.M010842200","article-title":"Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine\/threonine survival kinase gene, sgk-1","volume":"276","author":"Mikosz","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"Pt 2","key":"10.1016\/j.bbapap.2013.01.041_bb0520","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1042\/0264-6021:3390319","article-title":"Activation of serum- and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2","volume":"339","author":"Kobayashi","year":"1999","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0525","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1093\/emboj\/18.11.3024","article-title":"Serum and glucocorticoid-inducible kinase (SGK) is a target of the PI 3-kinase-stimulated signaling pathway","volume":"18","author":"Park","year":"1999","journal-title":"EMBO J."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0530","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/ncb1183","article-title":"Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive","volume":"6","author":"Jacinto","year":"2004","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0535","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0540","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7164\/antibiotics.28.721","article-title":"Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle","volume":"28","author":"Vezina","year":"1975","journal-title":"J. Antibiot. (Tokyo)"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0545","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1126\/science.1702904","article-title":"Chemistry and biology of the immunophilins and their immunosuppressive ligands","volume":"251","author":"Schreiber","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0550","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1126\/science.273.5272.239","article-title":"Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP","volume":"273","author":"Choi","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0555","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1021\/ja043277y","article-title":"Characterization of the FKBP.rapamycin. FRB ternary complex","volume":"127","author":"Banaszynski","year":"2005","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0560","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1006\/cimm.1995.1100","article-title":"Dominant mutations confer resistance to the immunosuppressant, rapamycin, in variants of a T cell lymphoma","volume":"163","author":"Dumont","year":"1995","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0565","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/eji.1830250239","article-title":"FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells","volume":"25","author":"Fruman","year":"1995","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0570","doi-asserted-by":"crossref","first-page":"27531","DOI":"10.1074\/jbc.270.46.27531","article-title":"TOR mutations confer rapamycin resistance by preventing interaction with FKBP12\u2013rapamycin","volume":"270","author":"Lorenz","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0575","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00007890-199707150-00008","article-title":"SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo","volume":"64","author":"Schuler","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0580","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12154-008-0003-5","article-title":"Rapamycin and mTOR kinase inhibitors","volume":"1","author":"Ballou","year":"2008","journal-title":"J. Chem. Biol."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0585","first-page":"1527","article-title":"Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor\/medulloblastoma models as single agent and in combination chemotherapy","volume":"61","author":"Geoerger","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0590","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1200\/JCO.2005.23.622","article-title":"Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study","volume":"23","author":"Galanis","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0595","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10637-005-1444-0","article-title":"Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme","volume":"23","author":"Chang","year":"2005","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0600","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ejca.2011.09.021","article-title":"Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma","volume":"48","author":"Geoerger","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0605","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0610","first-page":"3141","article-title":"PI3K\/mTOR signaling pathways in medulloblastoma","volume":"32","author":"Mohan","year":"2012","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0615","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1158\/0008-5472.CAN-09-2340","article-title":"Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2","volume":"70","author":"Yu","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0620","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/978-1-61779-430-8_22","article-title":"Inhibition of PI3K\u2013Akt\u2013mTOR signaling in glioblastoma by mTORC1\/2 inhibitors","volume":"821","author":"Fan","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0625","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1158\/1535-7163.MCT-05-0068","article-title":"Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor\/insulin receptor substrate-1\/phosphatidylinositol 3-kinase cascade","volume":"4","author":"Shi","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0630","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ccr.2006.03.029","article-title":"A dual PI3 kinase\/mTOR inhibitor reveals emergent efficacy in glioma","volume":"9","author":"Fan","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0635","doi-asserted-by":"crossref","first-page":"7960","DOI":"10.1158\/0008-5472.CAN-07-2154","article-title":"A dual phosphoinositide-3-kinase alpha\/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma","volume":"67","author":"Fan","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0640","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-08-0017","article-title":"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity","volume":"7","author":"Maira","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0645","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1158\/1535-7163.MCT-09-0160","article-title":"NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas","volume":"8","author":"Liu","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0650","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4161\/cc.8.3.7643","article-title":"Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma","volume":"8","author":"Guillard","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0655","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1158\/1535-7163.MCT-07-0393","article-title":"Characterization of structurally distinct, isoform-selective phosphoinositide 3\u2032-kinase inhibitors in combination with radiation in the treatment of glioblastoma","volume":"7","author":"Chen","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0660","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1593\/neo.111512","article-title":"The dual PI3K\/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses","volume":"14","author":"Mukherjee","year":"2012","journal-title":"Neoplasia"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0665","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer","volume":"118","author":"Carracedo","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0670","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1158\/0008-5472.CAN-08-3260","article-title":"Combined inhibition of MEK and mammalian target of rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their proliferation","volume":"69","author":"Paternot","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0675","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/stem.521","article-title":"Crosstalk between the PI3K\/mTOR and MEK\/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells","volume":"28","author":"Sunayama","year":"2010","journal-title":"Stem Cells"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0680","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/onc.2010.513","article-title":"Activated MEK cooperates with Ink4a\/Arf loss or Akt activation to induce gliomas in vivo","volume":"30","author":"Robinson","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0685","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1158\/0008-5472.CAN-12-0334","article-title":"Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency","volume":"72","author":"See","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0690","doi-asserted-by":"crossref","first-page":"7405","DOI":"10.1128\/MCB.00760-07","article-title":"Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation","volume":"27","author":"Wang","year":"2007","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0695","doi-asserted-by":"crossref","first-page":"ra81","DOI":"10.1126\/scisignal.2001017","article-title":"Akt and autophagy cooperate to promote survival of drug-resistant glioma","volume":"3","author":"Fan","year":"2010","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bbapap.2013.01.041_bb0700","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1038\/onc.2009.215","article-title":"The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair","volume":"28","author":"Westhoff","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0705","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.1199498","article-title":"The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling","volume":"332","author":"Hsu","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.bbapap.2013.01.041_bb0710","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1126\/science.1199484","article-title":"Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling","volume":"332","author":"Yu","year":"2011","journal-title":"Science"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570963913000605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570963913000605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T02:31:15Z","timestamp":1595385075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570963913000605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":142,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S1570963913000605"],"URL":"https:\/\/doi.org\/10.1016\/j.bbapap.2013.01.041","relation":{},"ISSN":["1570-9639"],"issn-type":[{"value":"1570-9639","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming resistance to rapalogs in gliomas by combinatory therapies","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbapap.2013.01.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}